NM-2201 (also known as CBL-2201) is an indole-based synthetic cannabinoid that is presumably a full agonist and unselectively binds to CB1 and CB2 receptors with low nanomolar affinity, the potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors, respectively. Little to no research data available on this chemical makes it impossible to describe it’s properties in detail.
NM-2201 is a synthetic cannabinoid is similar in structure to AM-2201, differing by an ester linking the 3’ position to the naphthyl group. This drug was discovered by Alexandros Makriyannis from Northeastern University.The physiological and toxicological properties of this compound are not currently known.This product is intended for forensic and research applications.
NM2201 is an analog of AM2201 , the potent synthetic cannabinoid (CB) with Ki values of 1.0 and 2.6 nM for the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors, respectively. The physiological actions of NM2201 have not been characterized. NM2201 is regulated as a Schedule I compound in the United States. This product is intended for forensic and research applications.
